查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836791

非小细胞肺癌药物市场（依治疗类型、治疗线、生物标记表达及销售管道）——2025-2032 年全球预测

Non-small Cell Lung Cancer Therapeutics Market by Treatment Type, Line Of Therapy, Biomarker Expression, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年非小细胞肺癌药物市场将成长至 332 亿美元，复合年增长率为 7.99%。

主要市场统计数据
基准年2024年 179.4亿美元
预计2025年 194亿美元
预测年份：2032年 332亿美元
复合年增长率（%） 7.99%

不断发展的非小细胞肺癌治疗前景：关注临床重点、付款人转变和转化前景

非小细胞肺癌 (NSCLC) 仍然是癌症治疗的核心挑战，需要整合临床创新、支付者协调和营运准备。过去十年的进展扩大了治疗选择，也使决策路径更加复杂，迫使临床医生和医疗系统在疗效、毒性和长期管理之间寻求平衡。本分析强调了治疗科学与系统层面必要性的交汇，为领导者在当前环境下指明了方向。

引言部分透过核准近期的监管审批、生物标誌物主导范式的演变以及组合方案对实践模式的影响，为本书奠定了基础。引言还重点介绍了最有可能带来回报的战略关注领域，包括优化可操作生物标誌物的诊断工作流程、使处方策略与实际结果保持一致，以及投资于证据生成以支持基于价值的合约。透过阐明问题和优先事项，本书为读者提供了后续深入章节的简明蓝图。

重塑非小细胞肺癌治疗和发展中的治疗流程和相关人员奖励的新治疗和诊断创新

非小细胞肺癌的治疗格局正因科学创新、监管格局的演变以及新的治疗模式而改变。免疫肿瘤学的改进、标靶药物的优化以及联合用药策略正在推动治疗方法顺序和关键临床试验设计的变革。同时，监管机构越来越重视生物标记定义的人群和核准后证据，这加速了分层发展，但也对诊断能力和真实世界数据基础设施的需求日益增加。

同时，支付方动态和价值框架正在转向基于结果的安排，这迫使製造商和医疗系统在研发早期整合卫生经济学和结果研究。诊断技术的进步，包括次世代定序和液态切片的广泛应用，使得患者选择更加精准，但需要在实验室网路和临床医生教育方面进行投资。这些因素的共同作用正在创造一个新的竞争前沿，临床差异化、诊断能力和商业性敏捷性将决定企业的长期定位。

评估2025年美国对非小细胞肺癌药物供应链、临床试验和病患所取得的关税

2025年美国关税的实施将进一步加剧非小细胞肺癌治疗药物的供应链、临床试验物流和下游准入的复杂性。关税带来的成本压力将波及原料药采购、成品进口和生产计划，使製造商、经销商和供应商容易受到采购延迟和利润压力的影响。这些营运影响将直接影响依赖稳定供应的临床项目以及需要跨地区库存同步的上市活动。

此外，关税可能会改变伴随诊断用品和实验室耗材的经济状况，从而限制生物标记检测的快速普及。临床试验赞助者可能面临支持国际临床实验试验地点和运输临床实验产品的成本增加，迫使他们调整方案并制定紧急时应对计画。健康系统和付款方可能会加强利用率控制，以应对采购成本的增加，从而更加重视强有力的真实世界证据，以证明比较价值并维持患者可及性。最终效果将是重新强调供应链的韧性、多样化的筹资策略以及积极主动的相关人员参与，以减轻可及性中断的影响。

細項分析揭示了治疗类型的区别、治疗方案的考虑、生物标记定义的队列以及为治疗方法采用提供资讯的管道动态

详细查看细分情况可发现治疗方法选择和商业性途径如何在多个方面出现分歧。根据治疗类型，化疗、免疫疗法和标靶治疗是核心类别，其中免疫疗法进一步分为 CTLA-4 抑制剂、PD-1 抑制剂和 PD-L1 抑制剂。在 CTLA-4 抑制剂中，Ipilimumab等药物体现了联合策略中使用的较老类型药物的作用机制，而 PD-1 抑制剂（如Nivolumab和Pembrolizumab）和 PD-L1 抑制剂（如Atezolizumab、 Avelumab和Durvalumab）则展示了查核点抑制剂类别中的广度及其在当前抑制剂类别中的广度。标靶治疗涵盖 ALK 抑制剂、BRAF 抑制剂、EGFR 抑制剂和 ROS1 抑制剂，其中 EGFR 类药物本身经历了第一代、第二代和第三代药物的发展，每一代都反映了疗效、抗药性管理和耐受性的改进。

一线、二线和三线治疗各自表现出独特的临床和商业性动态。根据生物标记状态，第一线治疗包括化疗、联合治疗、免疫治疗和标靶治疗。第二线及以上治疗同样结合了化疗、联合治疗、免疫治疗和分子标靶治疗，其决策在很大程度上受到既往治疗史、不断发展的抗药性机制和患者的功能状态的影响。生物标记表达进一步将患者细分为 ALK 重排、EGFR 突变、PD-L1 高表达和 KRAS 突变定义的群组，从而区分了标靶治疗、查核点抑制剂或联合治疗的合格。分销管道细分——医院药房、线上药房和零售药房——影响着患者的获取、配药物流和依从性支持计划，特别是对于依赖门诊分销的门诊病人标靶治疗。这些细分维度结合在一起形成一个复杂的矩阵，其中临床疗效、诊断能力和管道执行决定了采用模式和治疗顺序。

各地区非小细胞肺癌治疗的治疗方法采用、监管差异和医疗保健能力进行比较

区域动态显着影响非小细胞肺癌 (NSCLC) 药物的采用、资金筹措和管理方式。在美洲，报销途径和大型综合医疗系统使得新型药物能够快速引入，但付款方要求和州级处方流程的多样性要求製造商制定多方面的可及性策略。该地区的研究基础设施支持着强大的本地临床试验活动和生物标誌物主导治疗方法的快速应用，但可负担性的争论仍在影响着政策讨论和覆盖决策。

欧洲、中东和非洲呈现多种管理体制和支付模式，国家卫生技术评估流程和集中核准交互作用，导致病患取得药物的时间安排各有不同。已建立卫生技术评估 (HTA) 框架的国家要求儘早证明比较有效性，而该地区的新兴市场则强调成本控制，可能优先考虑学名药和低成本替代品。亚太地区各国的诊断可近性和报销情况差异显着，而一些拥有高产能的市场正快速普及。群体遗传变异，例如某些国家特定作用机制突变的盛行率较高，会影响临床试验设计和标靶药物的优先排序。在所有地区，本地产能、诊断网络和政策环境都会影响新治疗模式转化为常规实践的速度。

领先的生物製药和诊断公司的策略概况，重点关注非小细胞肺癌领域的管道差异化、合作模式和商业化方法

非小细胞肺癌 (NSCLC) 领域的企业策略取决于在产品线差异化、伙伴关係模式和商业执行之间取得平衡。领先的研发机构正在投资强大的转化项目，将机制洞察与生物标记开发相结合，从而实现更有针对性的标记策略，并实现与竞争对手的差异化定位。生物製药公司、诊断供应商和委外研发机构之间的策略联盟，利用互补优势，加速生物标记检验，并扩大临床试验入组。

商业性方法强调整合病人支持、诊断赋能和支付方证据产生。成功的公司将围绕着以结果为导向的叙事，协调医疗事务、市场准入和商业团队，从而与医疗系统和支付方产生共鸣。此外，那些在产品组合管理方面展现出敏捷性的公司，例如将资源导向高价值组合和创新机制，往往能够保持产品上市势头，并抓住临床相关的利基市场。透过观察竞争对手的行为，领导者可以发现伙伴关係机会、许可路径和邻近疗法，从而在降低开发风险的同时扩大目标患者群体。

可操作的建议，帮助行业领导者优化临床策略，加速治疗方法采用，并调整商业模式以改善护理

产业领导者应采取一系列切实可行的优先事项，将科学进步转化为持续的临床和商业性成果。实施针对 ALK、EGFR、PD-L1 和 KRAS 的稳健检测途径，将最大限度地选择合适的患者并缩短治疗时间。其次，证据生成必须超越随机试验，涵盖真实世界有效性和卫生经济学分析，以支持报销讨论和基于结果的合约。

第三，供应链多元化和紧急计画对于缓解阻碍药物取得的关税相关风险和地缘政治风险至关重要。第四，领导者应设计强调病人引导和依从性支持的商业模式，尤其要关注在医院、线上或零售药局销售的口服标靶药物。最后，建立跨部门伙伴关係——包括製造商、诊断供应商、支付方和医疗保健系统之间的合作伙伴关係——可以加速组合方案的采用，并实现风险共担，使奖励与患者疗效相一致。

采用严格的混合方法，说明资料来源、专家访谈以及用于得出临床、监管和商业性结论的分析框架

本研究采用严格的混合方法，结合一手资料和二手资料，整合临床、监管和商业洞察。一手资料包括对肿瘤科医生、付款方和诊断领域领导者的深入专家访谈、对付款方提交资料的审查以及临床指南分析。二手资料包括同行评审文献、监管备案文件和公开的临床试验註册库，以支持机制和结果数据。

此分析框架整合了定性输入的主题编码，并与已发表的疗效和安全性资料进行三角比较。诊断盛行率和生物标记分布在群体遗传学和检测基础设施的背景下进行解读。商业性结论源自于报销途径分析和相关人员回馈，旨在得出实际意义。方法学保障措施包括交叉验证、假设的透明记录以及临床和市场准入专家的迭代评审，以确保稳健性。

结论性综合强调了非小细胞肺癌治疗的策略性曲折点、合作的必要性以及改善疗效的途径

最终总结强调了临床创新、诊断验证和策略性商业性执行的整合对疗效的影响。最重要的曲折点是及时的生物标记检测、弹性供应网络以及将新机制与有意义的患者获益联繫起来的证据生成。合作开发包括与诊断合作伙伴的共同开发、与付款方就真实世界疗效指标达成一致，以及简化复杂方案启动和监测的整合照护模式。

同时优先考虑这些核心要素的领导者将更有能力将治疗潜力转化为持续的患者获益。本结论强调了跨职能投资、与报销相关人员的早期沟通以及持续从真实世界临床结果中学习以根据新数据调整策略的必要性。透过关注这些切实可行的途径，组织可以支持广泛且公平地获取非小细胞肺癌治疗的进展。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 针对非小细胞肺癌EGFR和MET抗药性路径的新兴双特异性抗体疗法
  • 越来越多地采用循环肿瘤 DNA 检测来早期发现和监测非小细胞肺癌 (NSCLC) 的治疗
  • 人工智慧成像和诊断集成，为 NSCLC 提供个人化治疗方案和结果
  • 开发一种新型 KRAS G12C 抑制剂，可有效治疗先前难治性 NSCLC 亚型
  • 增加下一代 ALK 抑制剂的投资，以克服非小细胞肺癌患者的抗药性突变
  • 扩大辅助免疫治疗试验，评估早期非小细胞肺癌 (NSCLC) 术后查核点抑制剂的疗效
  • 组织独立的 NTRK 融合治疗方法的兴起使得针对整个基因谱的 NSCLC标靶治疗成为可能
  • 基于奈米颗粒的药物传输系统的进展提高了肺肿瘤特异性并降低了毒性
  • PD-1/PD-L1联合治疗与化疗在非小细胞肺癌（NSCLC）第一线治疗的核准及市场渗透核准
  • 使用新辅助化疗通讯协定来提高非小细胞肺癌（NSCLC）的病理反应率正在迅速增加

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章非小细胞肺癌药物市场（依治疗类型）

  • 化疗
  • 免疫疗法
    • CTLA-4抑制剂
      • Ipilimumab
    • PD-1抑制剂
      • Nivolumab
      • Pembrolizumab
    • PD-L1抑制剂
      • Atezolizumab
      • Avelumab
      • Durvalumab
  • 标靶治疗
    • ALK抑制剂
    • BRAF抑制剂
    • EGFR抑制剂
      • 第一代
      • 第二代
      • 第三代
    • ROS1抑制剂

9. 非小细胞肺癌药物市场治疗线

  • 第一行
    • 化疗
    • 联合治疗
    • 免疫疗法
    • 标靶治疗
  • 第二行
    • 化疗
    • 联合治疗
    • 免疫疗法
    • 标靶治疗
  • 第三次及以后
    • 化疗
    • 联合治疗
    • 免疫疗法
    • 标靶治疗

第 10 章非小细胞肺癌药物市场（依生物标记表达）

  • ALK 重新配置
  • EGFR突变体
  • PD-L1高表达
  • KRAS突变体

第11章非小细胞肺癌药物市场（依分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

第十二章非小细胞肺癌药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章非小细胞肺癌药物市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章非小细胞肺癌药物市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Amgen Inc.
    • AstraZeneca PLC
    • BeiGene, Ltd.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
Product Code: MRR-036C5CF3B524

The Non-small Cell Lung Cancer Therapeutics Market is projected to grow by USD 33.20 billion at a CAGR of 7.99% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 17.94 billion
Estimated Year [2025] USD 19.40 billion
Forecast Year [2032] USD 33.20 billion
CAGR (%) 7.99%

An orientation to the evolving non-small cell lung cancer therapeutic landscape highlighting clinical priorities, payer shifts, and translational prospects

Non-small cell lung cancer (NSCLC) remains a central challenge in oncology practice, requiring a synthesis of clinical innovation, payer alignment, and operational readiness. Advances over the past decade have expanded treatment options and complicated decision pathways, driving clinicians and health systems to balance efficacy, toxicity, and long-term management considerations. This analysis foregrounds the intersection of therapeutic science and system-level imperatives to equip leaders with a clear orientation to the current environment.

The introduction sets the stage by contextualizing recent regulatory approvals, evolving biomarker-driven paradigms, and the impact of combination regimens on practice patterns. It also signals where strategic attention will most likely yield returns: optimizing diagnostic workflows for actionable biomarkers, aligning formulary strategies with real-world outcomes, and investing in evidence generation to support value-based contracting. By framing problems and priorities upfront, the reader gains a concise roadmap for the deeper sections that follow.

Emerging therapeutic and diagnostic innovations reshaping treatment algorithms and stakeholder incentives across non-small cell lung cancer care and development

The NSCLC landscape is undergoing transformative shifts driven by scientific innovation, regulatory evolution, and emergent care delivery models. Immuno-oncology refinements, targeted agent optimization, and combination strategies are changing the calculus for sequencing therapies and for the design of pivotal clinical trials. Concurrently, regulatory bodies increasingly emphasize biomarker-defined populations and post-approval evidence, which accelerates stratified development but raises demands on diagnostic capacity and real-world data infrastructures.

In parallel, payer dynamics and value frameworks are shifting toward outcomes-based arrangements, compelling manufacturers and health systems to integrate health economics and outcomes research earlier in development. Advances in diagnostics, including broader adoption of next-generation sequencing and liquid biopsies, enable more precise patient selection but require investment in lab networks and clinician education. Together, these forces are creating new competitive frontiers where clinical differentiation, diagnostic enablement, and commercial agility determine long-term positioning.

Assessment of 2025 United States tariffs on supply chains, clinical trials, and patient access to non-small cell lung cancer therapies

The introduction of United States tariffs in 2025 has introduced additional complexity across supply chains, trial logistics, and downstream access for NSCLC therapies. Tariff-driven cost pressures ripple through active pharmaceutical ingredient sourcing, finished product imports, and manufacturing schedules, which can create procurement delays and margin sensitivities for manufacturers, distributors, and providers. These operational impacts have direct implications for clinical programs that depend on uninterrupted supply and for launch activities that require synchronized inventory across regions.

Moreover, tariffs can alter the economics of companion diagnostic supply and laboratory consumables, potentially constraining rapid adoption of biomarker testing. Trial sponsors may face increased costs for international site support or for shipping investigational products, prompting protocol adjustments and contingency planning. Health systems and payers responding to increased acquisition costs may tighten utilization controls, which raises the importance of robust real-world evidence to demonstrate comparative value and to preserve patient access. The net effect is a renewed emphasis on supply chain resilience, diversified sourcing strategies, and proactive stakeholder engagement to mitigate access interruptions.

Segmentation analysis revealing treatment type distinctions, therapy line considerations, biomarker-defined cohorts, and channel dynamics informing therapy adoption

A granular view of segmentation reveals how therapeutic choices and commercial pathways diverge across multiple axes. Based on treatment type, core categories include chemotherapy, immunotherapy, and targeted therapy, with immunotherapeutic modalities further delineated into CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors. Within CTLA-4 inhibitors, agents such as ipilimumab exemplify older-class mechanisms used in combination strategies, while PD-1 inhibitors like nivolumab and pembrolizumab, and PD-L1 inhibitors such as atezolizumab, avelumab, and durvalumab, demonstrate the breadth of the checkpoint inhibitor class and its central role in current regimens. Targeted therapy spans ALK inhibitors, BRAF inhibitors, EGFR inhibitors, and ROS1 inhibitors, and the EGFR class itself unfolds across first-, second-, and third-generation agents, each generation reflecting improvements in potency, resistance profile management, and tolerability.

When viewed through the line-of-therapy lens, first-line, second-line, and third-or-later settings each present unique clinical and commercial dynamics, with first-line options encompassing chemotherapy, combination therapy, immunotherapy, and targeted therapy based on biomarker status. Second-line and later lines similarly incorporate chemotherapy, combination regimens, immunotherapy, and targeted approaches, but decisions are heavily influenced by prior exposure, evolving resistance mechanisms, and patient functional status. Biomarker expression further segments patients into groups defined by ALK rearrangement, EGFR mutation, high PD-L1 expression, and KRAS mutation, driving differential eligibility for targeted agents, checkpoint inhibitors, or combinations. Distribution channel segmentation - hospital pharmacy, online pharmacy, and retail pharmacy - shapes patient access, dispensing logistics, and adherence support programs, especially for oral targeted therapies that rely on outpatient distribution. Together, these segmentation dimensions create a complex matrix in which clinical efficacy, diagnostic capacity, and channel execution determine adoption patterns and therapeutic sequencing.

Comparative regional insights into therapeutic adoption, regulatory variation, and healthcare capacity shaping non-small cell lung cancer care across regions

Regional dynamics substantially influence how NSCLC therapeutics are adopted, financed, and administered. In the Americas, reimbursement pathways and large integrated health systems can facilitate rapid adoption of novel agents, but heterogeneity in payer requirements and state-level formulary processes means manufacturers must deploy multifaceted access strategies. The region's research infrastructure supports robust local trial activity and accelerated uptake for biomarker-driven therapies, but affordability debates continue to shape policy discourse and coverage decisions.

Europe, Middle East & Africa presents a mosaic of regulatory regimes and payer models where national health technology assessment processes and centralized approvals interact to create varied timelines for patient access. Countries with established HTA frameworks require early demonstration of comparative effectiveness, while emerging markets within the region emphasize cost containment and may prioritize generics or lower-cost alternatives. Asia-Pacific is characterized by rapid adoption in some high-capacity markets alongside significant variability in diagnostic availability and reimbursement across nations. Variations in population genetics, such as higher prevalence of certain actionable mutations in specific countries, influence clinical trial design and prioritization of targeted agents. Across all regions, local manufacturing capacity, diagnostic networks, and policy environments determine how swiftly new therapeutic paradigms translate into routine care.

Strategic profiles of leading biopharmaceutical and diagnostics companies highlighting pipeline differentiation, partnership models, and commercialization approaches in non-small cell lung cancer

Company strategies in NSCLC are defined by how organizations balance pipeline differentiation, partnership models, and commercial execution. Leading firms invest in robust translational programs to link mechanism-of-action insights with biomarker development, enabling more targeted label strategies and differentiated positioning against competing agents. Strategic collaborations among biopharma, diagnostics providers, and contract research organizations accelerate biomarker validation and expand trial enrollment by leveraging complementary capabilities.

Commercial approaches emphasize integrated patient support, diagnostics enablement, and payer evidence generation. Successful companies align medical affairs, market access, and commercial teams around outcome-based narratives that resonate with health systems and payers. Additionally, firms that demonstrate agility in portfolio management - reallocating resources toward high-value combinations or novel mechanisms - tend to preserve launch momentum and capture clinically relevant niches. Observing competitor behaviors, leaders can identify partnership opportunities, licensing paths, and therapeutic adjacencies that reduce development risk while expanding addressable patient populations.

Actionable recommendations to enable industry leaders optimize clinical strategies, accelerate therapeutic adoption, and align commercial models to improve care

Industry leaders should pursue a set of actionable priorities to convert scientific advances into durable clinical and commercial outcomes. First, integrating diagnostic capacity with therapeutic launches is essential; implementing robust testing pathways for ALK, EGFR, PD-L1, and KRAS will maximize appropriate patient selection and reduce time-to-treatment. Second, evidence generation must extend beyond randomized trials to include real-world effectiveness and health economic analyses that support reimbursement discussions and outcomes-based contracting.

Third, supply chain diversification and contingency planning are critical to mitigate tariff-related and geopolitical risks that can interrupt access. Fourth, leaders should design commercial models that emphasize patient navigation and adherence support, particularly for oral targeted agents distributed through hospital, online, or retail pharmacies. Finally, fostering cross-sector partnerships - between manufacturers, diagnostics providers, payers, and healthcare systems - will accelerate adoption of combination regimens and enable shared-risk arrangements that align incentives around patient outcomes.

Rigorous mixed-method approach describing data sources, expert interviews, and analytical frameworks that inform clinical, regulatory, and commercial conclusions

This research applies a rigorous mixed-method approach combining primary and secondary evidence to synthesize clinical, regulatory, and commercial insights. Primary research included in-depth expert interviews with oncologists, payers, and diagnostics leaders, alongside payer dossier reviews and clinical guideline analyses. Secondary research encompassed peer-reviewed literature, regulatory filings, and publicly available clinical trial registries to corroborate mechanistic and outcomes data.

Analytical frameworks integrated thematic coding of qualitative inputs with triangulation against published efficacy and safety data. Diagnostic prevalence and biomarker distributions were interpreted in the context of population genetics and testing infrastructure. For commercial conclusions, reimbursement pathway analysis and stakeholder feedback were synthesized to derive practical implications. Throughout, methodological safeguards included source cross-validation, transparently documented assumptions, and iterative review with clinical and market access experts to ensure robustness.

Concluding synthesis emphasizing strategic inflection points, collaborative imperatives, and pathways to improve outcomes in non-small cell lung cancer care

The concluding synthesis distills where clinical innovation, diagnostics enablement, and strategic commercial execution converge to influence outcomes. The most consequential inflection points involve timely biomarker testing, resilient supply networks, and evidence generation that links novel mechanisms to meaningful patient benefit. Collaborative imperatives span co-development with diagnostics partners, alignment with payers on real-world outcome metrics, and integrated care models that streamline initiation and monitoring of complex regimens.

Leaders who prioritize these axes concurrently will be better positioned to translate therapeutic potential into sustained patient benefit. The conclusion underscores the need for cross-functional investment, early engagement with reimbursement stakeholders, and continuous learning from real-world outcomes to adapt strategies as new data emerge. By focusing on these practical pathways, organizations can support broad, equitable access to advances in non-small cell lung cancer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of bispecific antibody therapies targeting EGFR and MET resistance pathways in NSCLC
  • 5.2. Growing adoption of circulating tumor DNA assays for early detection and treatment monitoring in NSCLC
  • 5.3. Integration of AI-driven imaging and diagnostics to personalize NSCLC treatment selection and outcomes
  • 5.4. Development of novel KRAS G12C inhibitors demonstrating efficacy in previously refractory NSCLC subtypes
  • 5.5. Increasing investment in next-generation ALK inhibitors to overcome resistance mutations in NSCLC patients
  • 5.6. Expansion of adjuvant immunotherapy trials assessing checkpoint inhibitors post-surgery in early-stage NSCLC
  • 5.7. Rise of tissue-agnostic therapies leveraging NTRK fusions for targeted NSCLC treatment across genetic profiles
  • 5.8. Advancements in nanoparticle-based drug delivery systems improving lung tumor specificity and reducing toxicity
  • 5.9. Approval and market uptake trends of PD-1/PD-L1 combination regimens with chemotherapy in first-line NSCLC
  • 5.10. Surge in use of neoadjuvant immunochemotherapy protocols to enhance pathologic response rates in NSCLC

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-small Cell Lung Cancer Therapeutics Market, by Treatment Type

  • 8.1. Chemotherapy
  • 8.2. Immunotherapy
    • 8.2.1. CTLA-4 Inhibitors
      • 8.2.1.1. Ipilimumab
    • 8.2.2. PD-1 Inhibitors
      • 8.2.2.1. Nivolumab
      • 8.2.2.2. Pembrolizumab
    • 8.2.3. PD-L1 Inhibitors
      • 8.2.3.1. Atezolizumab
      • 8.2.3.2. Avelumab
      • 8.2.3.3. Durvalumab
  • 8.3. Targeted Therapy
    • 8.3.1. ALK Inhibitors
    • 8.3.2. BRAF Inhibitors
    • 8.3.3. EGFR Inhibitors
      • 8.3.3.1. First Generation
      • 8.3.3.2. Second Generation
      • 8.3.3.3. Third Generation
    • 8.3.4. ROS1 Inhibitors

9. Non-small Cell Lung Cancer Therapeutics Market, by Line Of Therapy

  • 9.1. First Line
    • 9.1.1. Chemotherapy
    • 9.1.2. Combination Therapy
    • 9.1.3. Immunotherapy
    • 9.1.4. Targeted Therapy
  • 9.2. Second Line
    • 9.2.1. Chemotherapy
    • 9.2.2. Combination Therapy
    • 9.2.3. Immunotherapy
    • 9.2.4. Targeted Therapy
  • 9.3. Third Or Later
    • 9.3.1. Chemotherapy
    • 9.3.2. Combination Therapy
    • 9.3.3. Immunotherapy
    • 9.3.4. Targeted Therapy

10. Non-small Cell Lung Cancer Therapeutics Market, by Biomarker Expression

  • 10.1. ALK Rearrangement
  • 10.2. EGFR Mutant
  • 10.3. High PD-L1 Expression
  • 10.4. KRAS Mutant

11. Non-small Cell Lung Cancer Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Non-small Cell Lung Cancer Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Non-small Cell Lung Cancer Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Non-small Cell Lung Cancer Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Amgen Inc.
    • 15.3.2. AstraZeneca PLC
    • 15.3.3. BeiGene, Ltd.
    • 15.3.4. Bristol-Myers Squibb Company
    • 15.3.5. F. Hoffmann-La Roche Ltd.
    • 15.3.6. Merck & Co., Inc.
    • 15.3.7. Novartis AG
    • 15.3.8. Pfizer Inc.
    • 15.3.9. Regeneron Pharmaceuticals, Inc.
    • 15.3.10. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IPILIMUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ATEZOLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY AVELUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DURVALUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BRAF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ROS1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY THIRD OR LATER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY BIOMARKER EXPRESSION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ALK REARRANGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EGFR MUTANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HIGH PD-L1 EXPRESSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KRAS MUTANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL NO